TORONTO, ONTARIO--(Marketwire - April 15, 2011) - Arch Biopartners Inc ("Arch" or the "Company") (CNSX:ACH)(OTC:FOIFF) today announced it has granted 250,000 stock options with an exercise price of $0.90 per common share and a term of 5 years to a director, pursuant to the terms of the Company's stock option plan.
The price of Arch shares closed at $0.73 on April 14, 2011 on the CNSX.
About Arch Biopartners
Arch Biopartners is a portfolio based biotechnology company established to develop new products and technology for sale to pharmaceutical and industrial companies.
For more information on the Company, please consult the other public documents filed on SEDAR at www.sedar.com.
The Company's website address is: www.archbiopartners.com.
The CNSX has not reviewed and does not accept responsibility for the adequacy of this release.
Contact Information:
Richard Muruve
CEO
(647) 428 7031
info@archbiopartners.com
www.archbiopartners.com